Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)
NCT00457275
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
440
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypercholesterolemia
Interventions
DRUG:
MK0653, ezetimibe / Duration of Treatment: 4 Weeks
Sponsor
Organon and Co